Myriad advances cancer diagnostic
This article was originally published in The Gray Sheet
Executive Summary
Myriad Genetics introduces the BRACAnalysis Rearrangement DNA sequencing assay Aug. 1 for prediction of breast and ovarian cancer in high-risk women. The molecular test, which is the first commercially available to detect rare "large rearrangement" genetic mutations, will be used as an adjunct for "exceptionally" high-risk women who test negative with Myriad's already available BRACAnalysis test. A study published in the Journal of the American Medical Association in March signaled the need for such a test to help identify cancer-predisposing genes in up to 12% of high-risk women testing negative with Myriad's broader assay (1"The Gray Sheet" March 27, 2006, p. 15)...
You may also be interested in...
Myriad Genetics Says It Will Fill Gap In Cancer Risk Prediction
Myriad Genetics plans to release an advanced predict-tive genetic test for breast and ovarian cancer later this year, in line with study recommendations put forth in the Journal of the American Medical Association
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.